BERLIN, December 20 /PRNewswire-FirstCall/ -- Schering AG announced today that a dividend of EUR 1.20 per share will be proposed to the Annual General Meeting on April 19, 2006 based on a continuous positive business development in 2005. This equals an increase of 20 percent compared to the previous year.
Furthermore, Schering announced a settlement with Bayer AG regarding parts of the warranty claims asserted by Bayer. This settlement relates to the sale of Schering’s stake in the plant protection company Aventis CropScience in 2002. This will lead to a reversal of provisions with a positive one-time effect on the result after taxes of approximately seventy to a hundred million Euro.
This positive effect will partially compensate for potential negative one-time effects. These result from restructuring measures in regard to Schering’s FOCUS-program, which, among other things, includes a strategic realignment of its radiopharmaceutical business CIS bio International.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Your contacts at Corporate Communication:
Media Relations: Oliver Renner , T: +49-30-468-124-31, oliver.renner@schering.de
Investor Relations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
Find additional information at: www.schering.de/eng
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Schering AG
CONTACT: Your contacts at Corporate Communication: Media Relations: OliverRenner , T: +49-30-468-124-31, oliver.renner@schering.de; InvestorRelations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
